IDH1 and IDH2 Mutations in Gliomas

Long-term follow-up results of EORTC 26951: A randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors (AOD).

(2017) Martin J. Van Den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutant IDH1 is required for IDH1 mutated tumor cell growth

(2015) Genglin Jin et al.   Oncotarget

Cerebral Neoplasms in L-2 Hydroxyglutaric Aciduria: 3 New Cases and Meta-Analysis of Literature Data

(2012) Z. Patay et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Identification of Hedgehog pathway responsive glioblastomas by isocitrate dehydrogenase mutation

(2012) J. Gerardo Valadez et al.   CANCER LETTERS

Biphasic Papillary and Lobular Breast Carcinoma With PIK3CA and IDH1 Mutations

(2012) Daphne Ang et al.   DIAGNOSTIC MOLECULAR PATHOLOGY

Mutation Analysis of Isocitrate Dehydrogenase in Acute Lymphoblastic Leukemia

(2012) Yiqun Zhang et al.   Genetic Testing and Molecular Biomarkers

Glioma derived isocitrate dehydrogenase-2 mutations induced up-regulation of HIF-1α and β-catenin signaling: Possible impact on glioma cell metastasis and chemo-resistance

(2012) Yuejun Fu et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Progress in understanding 2-hydroxyglutaric acidurias

(2012) Martijn Kranendijk et al.   JOURNAL OF INHERITED METABOLIC DISEASE

IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas

(2012) Tareq A. Juratli et al.   JOURNAL OF NEURO-ONCOLOGY

Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation

(2012) Peppi Koivunen et al.   NATURE

IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics

(2012) Masato Sasaki et al.   NATURE

A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation

(2012) Robert B Jenkins et al.   NATURE GENETICS

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2005-2009

(2012) T. A. Dolecek et al.   NEURO-ONCOLOGY

IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo

(2011) Linda B. C. Bralten et al.   ANNALS OF NEUROLOGY

A Tale of Two Subunits: How the Neomorphic R132H IDH1 Mutation Enhances Production of αHG

(2011) Beth Pietrak et al.   BIOCHEMISTRY

A lymphoblast model for IDH2 gain-of-function activity in d-2-hydroxyglutaric aciduria type II: Novel avenues for biochemical and therapeutic studies

(2011) M. Kranendijk et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Glioma cells showing IDH1 mutation cannot be propagated in standard cell culture conditions

(2011) S Piaskowski et al.   BRITISH JOURNAL OF CANCER

Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases

(2011) Wei Xu et al.   CANCER CELL

IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma

(2011) Qi SongTao et al.   CANCER SCIENCE

Molecular Markers in Low-Grade Gliomas: Predictive or Prognostic?

(2011) C. Hartmann et al.   CLINICAL CANCER RESEARCH

IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours

(2011) M Fernanda Amary et al.   JOURNAL OF PATHOLOGY

Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome

(2011) Twinkal C Pansuriya et al.   NATURE GENETICS

An in vivo patient-derived model of endogenous IDH1-mutant glioma

(2011) H. A. Luchman et al.   NEURO-ONCOLOGY

IDH mutation status in prostate cancer

(2011) A F Ghiam et al.   ONCOGENE

Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping

(2011) D. R. Borger et al.   ONCOLOGIST

2-Hydroxyglutarate Production, but Not Dominant Negative Function, Is Conferred by Glioma-Derived NADP+-Dependent Isocitrate Dehydrogenase Mutations

(2011) Genglin Jin et al.   PLoS One

Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?

(2011) Stephanie E Combs et al.   Radiation Oncology

Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma

(2010) Houtan Noushmehr et al.   CANCER CELL

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

(2010) Maria E. Figueroa et al.   CANCER CELL

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

IDH1 mutant structures reveal a mechanism of dominant inhibition

(2010) Shimin Zhao et al.   CELL RESEARCH

Molecular mechanisms of “off-on switch” of activities of human IDH1 by tumor-associated mutation R132H

(2010) Bei Yang et al.   CELL RESEARCH

IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children’s Oncology Group

(2010) Ian F. Pollack et al.   CHILDS NERVOUS SYSTEM

Warburg tumours and the mechanisms of mitochondrial tumour suppressor genes. Barking up the right tree?

(2010) Jean-Pierre Bayley et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

Integrated Molecular Genetic Profiling of Pediatric High-Grade Gliomas Reveals Key Differences With the Adult Disease

(2010) Barbara S. Paugh et al.   JOURNAL OF CLINICAL ONCOLOGY

Oncometabolite? IDH1 Discoveries Raise Possibility of New Metabolism Targets in Brain Cancers and Leukemia

(2010) K. Garber   JNCI-Journal of the National Cancer Institute

DNA Methylation, Isocitrate Dehydrogenase Mutation, and Survival in Glioma

(2010) Brock C. Christensen et al.   JNCI-Journal of the National Cancer Institute

Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?

(2010) Nanne K Kloosterhof et al.   LANCET ONCOLOGY

Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis

(2010) J. Laffaire et al.   NEURO-ONCOLOGY

First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response

(2010) W. Taal et al.   NEURO-ONCOLOGY

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas

(2010) C. Houillier et al.   NEUROLOGY

All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2

(2010) M. Labussiere et al.   NEUROLOGY

Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome

(2009) Takuya Watanabe et al.   ACTA NEUROPATHOLOGICA

Monoclonal antibody specific for IDH1 R132H mutation

(2009) David Capper et al.   ACTA NEUROPATHOLOGICA

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas

(2009) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas

(2009) Takuya Watanabe et al.   AMERICAN JOURNAL OF PATHOLOGY

Mutant Metabolic Enzymes Are at the Origin of Gliomas

(2009) H. Yan et al.   CANCER RESEARCH

Analysis ofIDH1andIDH2mutations in Japanese glioma patients

(2009) Yukihiko Sonoda et al.   CANCER SCIENCE

IDH1mutations at residue p.R132 (IDH1R132) occur frequently in high-grade gliomas but not in other solid tumors

(2009) Fonnet E. Bleeker et al.   HUMAN MUTATION

Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers

(2009) Mi Ran Kang et al.   INTERNATIONAL JOURNAL OF CANCER

Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network

(2009) Michael Weller et al.   JOURNAL OF CLINICAL ONCOLOGY

Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas

(2009) Marc Sanson et al.   JOURNAL OF CLINICAL ONCOLOGY

NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

(2009) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

(2009) Lenny Dang et al.   NATURE

DO INTRACRANIAL NEOPLASMS DIFFER IN OLLIER DISEASE AND MAFFUCCI SYNDROME? AN IN-DEPTH ANALYSIS OF THE LITERATURE

(2009) Adrianna Ranger et al.   NEUROSURGERY

Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome

(2009) Elaine R. Mardis et al.   NEW ENGLAND JOURNAL OF MEDICINE

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

CANCER: Puzzling Patterns of Predisposition

(2009) P. J. Pollard et al.   SCIENCE

Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1 

(2009) S. Zhao et al.   SCIENCE

Analysis of the IDH1 codon 132 mutation in brain tumors

(2008) Jörg Balss et al.   ACTA NEUROPATHOLOGICA

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE